Developing a Novel Platform for More Efficient and Safe Biopharmaceutical ProductionJune 28, 2018
iConsensus launched with Support from the Innovative Medicines Initiative
PreSens is one of eight medium sized enterprises that together with four academic institutes and seven partners of the European Federation of Pharmaceutical Industries and Associations (EFPIA) form the international iConsensus consortium. iConsensus was launched in response to the 10th call of the Innovative Medicines Initiative (IMI) under IMI2 in Stockholm in May this year. It has the aim to develop a platform of novel analytical tools for more efficient and safe production of biopharmaceuticals.
Efficient and safe bio-production is important to facilitate the implementations and use of biopharmaceuticals, vaccines and advanced therapies. The iConsensus consortium aims at achieving a safer, faster, and more cost-effective process for the production of a wide range of biopharmaceuticals.
In the next four years the project will develop modular monitoring tools for real-time detection of physical factors, reagents and immunoglobulin G quality attributes in a bioreactor, a monitoring information database, modelling tools allowing efficient feedback control of the cultivation process, and new high-throughput production processes by high-performance parallel bioreactors.
PreSens' contribution will be the integration of optical sensor technology in sampling systems, microfluidics and bioreactors. An important part of the project will be the evaluation of industrial applicability of the tools and database for use in a good manufacturing practice (GMP) environment, relevant for industrial procdution processes based on animal cells.
Dr. Véronique Chotteau from the KTH Stockholm, representing the academic Coordinator of iConsensus, sees a unique opportunity in this project: "This is a fantastic opportunity to improve the manufacturing processes of biologics, both in the development process and in manufacturing. We will create access to real time information of the culture process that I, and all in the field, have dreamed of. This will be complemented by tools to exploit this information. This will provide a fastest and higher quality process development, as well as more robust and efficient manufacturing processes."
Universities and SMEs
Kungliga Tekniska Högskolan KTH Stockholm, Sweden
Université de Mons, Belgium
PreSens Precision Sensing GmbH, Germany
m2p-labs GmbH, Germany
Universität Hohenheim, Germany
Ipratech s.a, Belgium
Kantisto BV, Netherlands
Iprasense SAS, France
RWTH Aachen University, Germany
Micronit Microtechnologiesfluidics BV, Netherlands
PAIA Biotech GmbH, Germany
Svanholm.com ApS, Denmark
Sanofi-Aventis Deutschland GmbH, Germany
Rentschler Biopharma SE, Germany
Bayer Aktiengesellschaft, Germany
GlaxoSmithKline Research & Development Ltd, United Kingdom
Synthon Biopharmaceuticals BV, Netherlands
Pfizer ltd., United Kingdom
UCB Biopharma SPRL, Switzerland